| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444116 | European Journal of Cancer | 2013 | 8 Pages |
Abstract
In conclusion, only in tumours with a low EGFR fraction, adding hypoxia modification to AR has an additive beneficial effect on outcome. EGFR expression is a predictive biomarker for the selection of patients that will or will not respond to ARCON.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Monique M. Nijkamp, Paul N. Span, Christiaan H.J. Terhaard, Patricia A.H. Doornaert, Johannes A. Langendijk, Piet L.A. van den Ende, Martin de Jong, Albert J. van der Kogel, Johan Bussink, Johannes H.A.M. Kaanders,